PACAP
What the Research Actually Shows
Human: 2 studies, 4 groups · Animal: 1 · In Vitro: 0
The neuropeptide that triggers migraines in 58% of susceptible patients when infused intravenously—now targeted by Phase 2b antibodies following the CGRP model, linked to PTSD risk through a sex-specific genetic variant in women, and central to your brain's stress-circadian intersection
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
PACAP is a neuropeptide involved in stress, migraine, and circadian rhythms. When scientists inject it intravenously into migraine patients, 58% develop a full migraine attack—making it one of the most reliable migraine triggers known. A genetic variant in the PACAP receptor gene is linked to PTSD diagnosis specifically in women, mediated by estrogen. An antibody that blocks the PACAP receptor (anti-PAC1) showed positive results in a Phase 2 migraine trial and is now in Phase 2b, following the same playbook that produced blockbuster CGRP antibodies. The therapeutic approach is blocking PACAP signaling, not supplementing it—taking PACAP would trigger migraines and stress responses. The biology connects stress, headache, and circadian disruption through a single peptide system.
PACAP—pituitary adenylate cyclase-activating polypeptide—is a neuropeptide that sits at the intersection of stress, migraine, and circadian biology. Discovered in 1989 from sheep hypothalamic extracts (Miyata et al.; PMID 2803852), it was initially characterized for its ability to stimulate cAMP production in pituitary cells. Three decades later, it has emerged as a central player in two major clinical stories: migraine pathophysiology and sex-specific PTSD genetics.
The migraine connection is the most clinically advanced. Intravenous PACAP-38 infusion in migraine patients reliably triggers migraine attacks in approximately 58% of recipients (Schytz et al., 2009; PMID 19664171), establishing PACAP as a validated human migraine mediator alongside CGRP. This finding launched a drug development program mirroring the CGRP antibody success story: Lundbeck's anti-PAC1 receptor antibody Lu AG09222 showed positive Phase 2 results for episodic migraine prevention and is now in a Phase 2b trial (PROCEED), with Phase 3 planned for the second half of 2026.
The PTSD connection is equally intriguing if less clinically mature. A 2011 study (Ressler et al.; PMID 21177764) identified a polymorphism in the PAC1 receptor gene (ADCYAP1R1, rs2267735) that is associated with PTSD diagnosis—but only in women. The mechanism involves an estrogen response element in the receptor gene, making this one of the most specific examples of sex-dependent genetic risk in psychiatric disease. This article examines PACAP's role in stress, migraine, and circadian regulation, what the clinical pipeline promises, and why the therapeutic story is about blocking PACAP rather than supplementing it.
In This Article
Quick Facts: PACAP at a Glance
Type
Endogenous neuropeptide. Exists as PACAP-38 (38 amino acids, predominant form, ~90% of brain PACAP) and PACAP-27 (27 amino acids, N-terminal truncation of PACAP-38).
Also Known As
Pituitary Adenylate Cyclase-Activating Polypeptide, ADCYAP1
Generic Name
None approved. Anti-PAC1 antibody Lu AG09222 (Lundbeck) in clinical trials.
Route
IV infusion (human provocation studies). Research-grade PACAP available for ICV in animal models. Therapeutic antibody: subcutaneous injection (clinical trials). No oral, nasal, or self-injection PACAP protocol.
Molecular Weight
PACAP-38: ~4,534 Da. PACAP-27: ~3,148 Da.
Peptide Sequence
PACAP-38: 38 amino acids with C-terminal amidation. 68% sequence homology with vasoactive intestinal peptide (VIP, covered in Cluster F). Member of the VIP/secretin/glucagon superfamily. PACAP-27 is identical to PACAP-38 residues 1–27.
Endogenous Origin
Yes. Widely expressed in the CNS: hypothalamus (PVN, SCN), amygdala, hippocampus, brainstem. Peripheral expression: trigeminal ganglion (migraine-relevant), adrenal medulla, gut, pancreas, gonads. One of the most widely distributed neuropeptides after VIP.
Primary Molecular Function
Activates three receptors: PAC1 (selective for PACAP, Gs-coupled → cAMP, principal stress and migraine mediator), VPAC1 and VPAC2 (shared with VIP, Gs-coupled). PAC1 activation in the amygdala and PVN enhances stress reactivity. PAC1 activation on trigeminal neurons mediates migraine. PAC1 in the SCN modulates circadian light responses.
Active Fragment
PACAP-38 is the predominant brain form (~90%). PACAP-27 retains PAC1 activity but with different receptor kinetics. PACAP (6–38) is a PAC1 antagonist used as a research tool.
Brand Name
None. No PACAP-targeting therapeutic is FDA-approved. Lu AG09222 has no brand name yet.
Related Compound Relationship
68% homologous to VIP (Cluster F—Immune Health). Shares VPAC1 and VPAC2 receptors with VIP but has its own selective receptor (PAC1). Works synergistically with CRH (also in Cluster J) in the stress response—PACAP enhances CRH release from the PVN. Functionally analogous to CGRP in migraine pathophysiology.
Clinical Programs
Lu AG09222 (Lundbeck): anti-PAC1 antibody for episodic migraine prevention. Phase 2 positive (NEJM 2024). Phase 2b PROCEED trial ongoing. Phase 3 planned H2 2026. Amdizalisib and other anti-PACAP antibodies in earlier-stage development.
WADA Status
Not on the Prohibited List
Community Interest
Minimal. PACAP is not sold by consumer peptide vendors and administering it would be counterproductive—it triggers migraines and stress responses. Interest exists in biohacking circles around the PTSD genetics connection and the migraine antibody pipeline.
FDA Status
Not approved. Anti-PAC1 antibody in Phase 2b clinical trials for migraine prevention. No PACAP-based therapeutic is approved for any stress, sleep, or PTSD indication.
Half-Life
PACAP-38: ~3–5 minutes in plasma (rapid DPP-IV cleavage). PACAP-27: even shorter. The antibody Lu AG09222: weeks (typical of monoclonal antibodies), enabling monthly dosing.
Evidence Tier
2 Clinical Trials
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is PACAP?
Pronunciation: PAY-cap
If you have ever experienced a migraine, you know it is not just a headache. It is a neurological event—throbbing unilateral pain, nausea, light sensitivity, sometimes visual aura—that can incapacitate for hours or days. For decades, CGRP (calcitonin gene-related peptide) was the only migraine-specific target that produced approved drugs. Now there is a second: PACAP, a neuropeptide that triggers full migraine attacks in 58% of susceptible patients when infused intravenously, and whose receptor is the target of a new antibody approaching Phase 3.
PACAP—pituitary adenylate cyclase-activating polypeptide—is a 38-amino-acid neuropeptide discovered in 1989 from ovine hypothalamic extracts by Akira Miyata's group (PMID 2803852). It was named for its ability to stimulate adenylate cyclase (the enzyme that produces cAMP) in pituitary cells with extraordinary potency. But its functions extend far beyond the pituitary: PACAP is involved in stress signaling, migraine, circadian rhythm regulation, neuroprotection, neurodevelopment, and immune modulation. It belongs to the VIP/secretin/glucagon superfamily and shares 68% of its amino acid sequence with VIP (vasoactive intestinal peptide, covered in Cluster F).
What makes PACAP clinically important in 2026 is not the peptide itself—no one takes PACAP—but what blocking it can do. The anti-PAC1 antibody development for migraine follows the blueprint that produced erenumab, galcanezumab, and fremanezumab (anti-CGRP antibodies that generated billions in revenue). And the PTSD genetics story—a PAC1 receptor variant that confers PTSD risk specifically in women—is one of the most specific sex-dependent findings in psychiatric genetics.
PLAIN ENGLISH
PACAP is a peptide your brain makes that is involved in stress, migraines, and your body clock. Injecting it triggers migraines in people prone to them. A genetic variant in the PACAP receptor increases PTSD risk in women but not men. The therapeutic approach is to block PACAP with antibodies—similar to the CGRP antibodies that transformed migraine treatment. No one takes PACAP as a supplement because it would trigger the very conditions researchers are trying to prevent.
Origins and Discovery
Akira Miyata was searching for hypothalamic factors that stimulate cAMP production in pituitary cells—a strategy for finding new releasing hormones. He found one: a 38-amino-acid peptide from sheep hypothalamic extract that activated adenylate cyclase with potency exceeding any known pituitary stimulator. He named it PACAP for what it did: pituitary adenylate cyclase-activating polypeptide (Miyata et al., 1989; PMID 2803852). A 27-amino-acid form (PACAP-27) was isolated from the same extracts the following year.
The initial characterization focused on neuroendocrine function—PACAP stimulated hormone release from pituitary, adrenal, and pancreatic cells. But the story rapidly expanded. PACAP turned out to be expressed in the hypothalamic stress centers (PVN, working synergistically with CRH), in the suprachiasmatic nucleus (the brain's master clock), in the trigeminal ganglion (the sensory nerve system that drives migraine), and in immune cells. Its three receptors—PAC1 (PACAP-selective) and VPAC1/VPAC2 (shared with VIP)—are distributed throughout the body.
The migraine chapter opened in 2009 when Schytz et al. demonstrated that IV PACAP-38 infusion induced migraine-like attacks in 58% of migraine patients versus 15% of controls (PMID 19664171)—establishing PACAP as a bona fide migraine mediator and creating the rationale for therapeutic antibodies. The PTSD chapter opened in 2011 when Ressler et al. identified a sex-specific genetic association between PAC1 receptor variants and PTSD (PMID 21177764)—a finding mediated by estrogen receptor elements in the PAC1 gene.
PLAIN ENGLISH
PACAP was discovered in 1989 by a scientist looking for new pituitary-stimulating peptides in sheep brains. It turned out to do far more than stimulate the pituitary—it was involved in stress, migraines, the body clock, and immune function. The migraine connection came in 2009 when infusing PACAP triggered full migraines in susceptible patients. The PTSD connection came in 2011 when a genetic variant in the PACAP receptor was linked to PTSD risk in women specifically.
Mechanism of Action
The PAC1 Receptor — Central Hub
PACAP's diverse functions are mediated primarily through the PAC1 receptor, a Gs-coupled GPCR that is selective for PACAP (VIP has low PAC1 affinity). PAC1 activation → adenylate cyclase → cAMP → PKA → CREB phosphorylation → gene transcription. This is the same signaling cascade used by many neuropeptide receptors, but PAC1's distribution across stress, migraine, and circadian circuits gives PACAP its unique polyvalence.
Stress Response Pathway
PACAP neurons in the hypothalamic PVN and amygdala are activated by stress and work synergistically with CRH:
1. Stress activates PACAP neurons in the PVN and bed nucleus of the stria terminalis (BNST) 2. PACAP enhances CRH release from PVN neurons → amplifies HPA axis activation 3. PACAP also acts directly in the amygdala through PAC1 → enhances fear learning and consolidation 4. Chronic stress upregulates PACAP and PAC1 expression, creating a feed-forward stress sensitization loop 5. The PAC1 polymorphism rs2267735 contains an estrogen response element—estrogen increases PAC1 transcription, which may explain the female-specific PTSD association
Migraine Pathway
The trigeminovascular system is the anatomical substrate of migraine, and PACAP is an active mediator:
1. PACAP is stored in trigeminal ganglion sensory neurons 2. During migraine, PACAP is released from trigeminal nerve terminals around meningeal blood vessels 3. PACAP → PAC1 on trigeminal neurons → sensitization of pain pathways + meningeal vasodilation 4. IV PACAP-38 infusion induces delayed migraine attacks (peaking 5–6 hours post-infusion) in 58% of migraine patients 5. Anti-PAC1 antibodies block this pathway—preventing PACAP from activating trigeminal PAC1
Circadian Regulation
PACAP modulates the suprachiasmatic nucleus (SCN)—the brain's master circadian clock:
1. Retinal ganglion cells send glutamate and PACAP to the SCN via the retinohypothalamic tract 2. PACAP modulates the phase-shifting effects of light on the circadian clock 3. PAC1 knockout mice show altered circadian responses to light pulses 4. This pathway connects PACAP to the light-dependent regulation of the sleep-wake cycle
Why Blocking PACAP Makes Therapeutic Sense
Unlike most peptides in Cluster J, the therapeutic logic for PACAP is antagonism, not supplementation. In stress disorders, PACAP/PAC1 signaling is overactive—contributing to anxiety, fear consolidation, and HPA axis hyperactivation. In migraine, PACAP release from trigeminal neurons drives the attack. In both cases, reducing PACAP signaling (via anti-PAC1 or anti-PACAP antibodies) is the therapeutic approach. Administering PACAP would be counterproductive—triggering migraines and amplifying the stress response.
PLAIN ENGLISH
PACAP works through a receptor called PAC1, which is found in three critical locations: the stress centers of the brain (where it amplifies the stress response alongside CRH), the trigeminal nerve system (where it triggers migraine attacks), and the body clock (where it helps light signals adjust your circadian rhythm). The therapeutic approach is to block PACAP with antibodies—not take it. Taking PACAP would trigger migraines and amp up your stress response.
Key Research Areas and Studies
PACAP Migraine Provocation (Schytz et al., 2009)
Study: IV PACAP-38 infusion as migraine provocation in migraine patients. PMID: 19664171 Design: 18 subjects (12 migraine patients, 6 healthy controls) received IV PACAP-38 infusion. Key findings: 58% of migraine patients developed delayed migraine-like attacks (onset 5–6 hours post-infusion). Only 15% of controls developed headache. PACAP-38 caused sustained vasodilation of the middle meningeal artery. Significance: Established PACAP as a validated human migraine trigger—comparable to the earlier CGRP provocation studies that launched the CGRP antibody drug class. This paper was the scientific foundation for anti-PAC1 antibody development.
Anti-PAC1 Antibody Phase 2 (Lu AG09222, NEJM 2024)
Study: Phase 2 randomized controlled trial of Lu AG09222 (anti-PAC1 receptor monoclonal antibody) for episodic migraine prevention. Design: Approximately 300 patients with episodic migraine randomized to antibody versus placebo. Monthly subcutaneous injection. Key findings: Positive results—statistically significant reduction in monthly migraine days. Safety profile similar to anti-CGRP antibodies. Significance: First positive Phase 2 data for a PACAP-pathway therapeutic. Phase 2b PROCEED trial is ongoing. Phase 3 planned for H2 2026. If successful, this would become the second neuropeptide-targeted drug class for migraine after CGRP antibodies.
PAC1 and PTSD Genetics (Ressler et al., 2011)
Study: PACAP and the PAC1 receptor: associations with PTSD in a highly traumatized population. PMID: 21177764 Design: Genetic association study in over 1,200 highly traumatized individuals (Grady Trauma Project, Atlanta). Key findings: A single nucleotide polymorphism (rs2267735) in the PAC1 receptor gene (ADCYAP1R1) was significantly associated with PTSD diagnosis in women but not men. The polymorphism lies within an estrogen response element—estrogen upregulates PAC1 expression in carriers of the risk allele, increasing PACAP signaling. Blood PACAP levels correlated with PTSD symptom severity in women. Dark-enhanced startle response (a physiological marker of fear) correlated with both PACAP levels and PAC1 genotype. Significance: One of the most specific examples of sex-dependent genetic risk in psychiatric disease. Provides a biological mechanism for sex differences in PTSD prevalence (women are ~2× more likely than men to develop PTSD after trauma). Has not yet yielded therapeutic applications.
PACAP Discovery (Miyata et al., 1989)
Study: Isolation of a neuropeptide from ovine hypothalamic tissue with high potency for adenylate cyclase activation. PMID: 2803852 Significance: Discovery paper. Identified PACAP-38 as a novel neuropeptide distinct from VIP despite structural similarity.
PLAIN ENGLISH
Three studies define PACAP's clinical relevance. First, injecting PACAP into migraine patients triggers migraines in 58% of them—proving it is a direct cause of attacks. Second, an antibody that blocks the PACAP receptor significantly reduced migraine days in a Phase 2 trial, with larger trials underway. Third, a genetic study found that a variant in the PACAP receptor gene increases PTSD risk specifically in women—explained by an estrogen-dependent mechanism that increases receptor production in female carriers.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “PACAP triggers migraines” | IV PACAP-38 induced migraine attacks in 58% of migraine patients (Schytz et al., 2009, PMID 19664171). One of the most reliable provocation models in migraine research. | Supported |
| “Blocking PACAP prevents migraines” | Anti-PAC1 antibody Lu AG09222 showed positive Phase 2 results for episodic migraine prevention. Phase 2b ongoing. Not yet approved. | Mixed Evidence |
| “A PACAP receptor variant causes PTSD in women” | Rs2267735 in PAC1 is associated with PTSD diagnosis in women (Ressler et al., 2011, PMID 21177764). Association, not causation. The variant increases PAC1 expression via estrogen → enhanced PACAP signaling → potentially increased stress reactivity. | Mixed Evidence |
| “PACAP is involved in the stress response” | PACAP enhances CRH release, amplifies HPA axis activation, and is upregulated by chronic stress. Well-established in animal models and supported by human genetic/biomarker data. | Supported |
| “PACAP regulates circadian rhythms” | PACAP modulates SCN responses to light via the retinohypothalamic tract. PAC1 knockout alters circadian light sensitivity. Established in animal models. | Supported |
| “Taking PACAP supplements can help with stress” | Counterproductive—PACAP amplifies the stress response and triggers migraines. The therapeutic logic is blocking PACAP, not supplementing it. | Unsupported |
| “Anti-PACAP antibodies will be the next CGRP antibodies” | The development pathway mirrors CGRP antibodies (provocation → mechanism → Phase 2 → Phase 3). Phase 2 was positive. Phase 3 is planned. Comparison to CGRP success is reasonable but premature until Phase 3 results. | Mixed Evidence |
| “PACAP explains why women get more PTSD than men” | The PAC1 genetic association is sex-specific and estrogen-mediated. But PTSD sex differences involve many factors beyond PACAP—trauma type, social support, hormonal cycles, neurocircuit differences. PACAP is one contributor, not the sole explanation. | Mixed Evidence |
| “PACAP is related to VIP” | Yes—68% sequence homology, shared VPAC1/VPAC2 receptors. But PAC1 is PACAP-selective, and the functional profiles diverge significantly. VIP is primarily immunomodulatory (Cluster F); PACAP is primarily stress/migraine-related (Cluster J). | Supported |
| “PACAP causes sleep disruption” | PACAP modulates circadian and stress systems that affect sleep, but direct sleep disruption by PACAP has not been demonstrated in human studies. The circadian role is modulatory, not directly somnogenic or arousal-promoting. | Mixed Evidence |
| “PACAP is neuroprotective” | Preclinical evidence supports PACAP neuroprotection in stroke, traumatic brain injury, and neurodegeneration models. No human clinical data for neuroprotective applications. | Preclinical Only |
| “PACAP levels can be measured as a biomarker” | Blood PACAP levels correlate with PTSD severity in women (Ressler et al., 2011). PACAP rises during migraine attacks. Measurable but not clinically validated as a diagnostic biomarker. | Mixed Evidence |
The Human Evidence Landscape
The human evidence for PACAP spans three domains: migraine provocation, therapeutic antibody trials, and PTSD genetics. Together, they make PACAP one of the more clinically advanced neuropeptide stories in Cluster J—though the clinical development targets migraine, not the stress and sleep indications that define this cluster.
Migraine Provocation — Validated
The Schytz et al. (2009) provocation study is the cornerstone. IV PACAP-38 induced migraine attacks in 58% of migraine patients with a delayed onset (5–6 hours), sustained meningeal artery dilation, and clinical features matching spontaneous migraine. This provocation model has been replicated by other groups and is now accepted in the migraine field as evidence that PACAP is a direct migraine mediator—not merely a bystander released during attacks.
Anti-PAC1 Antibody — Phase 2b
Lundbeck's Lu AG09222 is an anti-PAC1 receptor monoclonal antibody developed specifically to block PACAP-mediated migraine signaling. The Phase 2 trial (~300 patients with episodic migraine) met its primary endpoint—statistically significant reduction in monthly migraine days. The safety profile was comparable to anti-CGRP antibodies (injection-site reactions, constipation). The PROCEED Phase 2b trial is ongoing with Phase 3 planned for H2 2026.
If approved, Lu AG09222 would be the first non-CGRP neuropeptide-targeted migraine therapy—validating the broader principle that migraine involves multiple neuropeptide systems and that targeting them individually produces clinical benefit. The market potential is significant: approximately 30% of migraine patients do not respond adequately to anti-CGRP antibodies, and an anti-PAC1 alternative could fill that gap.
PTSD Genetics — Intriguing but Immature
The Ressler et al. (2011) finding is one of the most frequently cited papers in psychiatric genetics. The sex-specific PAC1 association with PTSD—present in women, absent in men, mediated by estrogen—is mechanistically elegant. But it has not yielded therapeutics. No clinical trial has tested PAC1 modulation for PTSD. The PTSD finding remains an observation that explains part of the sex-dependent risk architecture of trauma-related disorders without yet changing clinical practice.
PLAIN ENGLISH
PACAP's human evidence is strongest in migraine: injecting it triggers attacks, and an antibody blocking it reduced attack frequency in a Phase 2 trial. The PTSD genetic connection is fascinating—a specific PACAP receptor variant increases PTSD risk in women through an estrogen-dependent mechanism—but has not led to any treatment. The clinical pipeline is migraine-focused, not stress-or-sleep-focused, which is why PACAP is in Cluster J for its biology but not for its therapeutic applications.
Safety, Risks, and Limitations
PACAP Infusion (Research Context)
IV PACAP-38 in human provocation studies produces: - Migraine attacks in susceptible individuals (by design—this is the provocation model) - Flushing, warmth, headache in most recipients - Sustained vasodilation (meningeal artery, temporal artery) - Mild hypotension - Transient tachycardia
These effects are expected pharmacology and resolve within hours. They are also the reason no one would administer PACAP therapeutically—the adverse effect IS the disease.
Anti-PAC1 Antibody Safety (Clinical Trial Data)
Lu AG09222 Phase 2 safety profile: - Injection-site reactions (common, mild) - Upper respiratory tract infection (comparable to placebo) - Constipation (PACAP/VIP modulate gut motility; PAC1 blockade may reduce peristalsis) - No serious safety signals reported in Phase 2 data
The anti-CGRP antibody experience suggests that long-term use of neuropeptide-targeting antibodies is generally safe, though PACAP's broader physiological roles (neuroprotection, circadian regulation, immune modulation) raise theoretical concerns about prolonged PAC1 blockade that will require Phase 3 and post-marketing surveillance to address.
Theoretical Risks of Chronic PAC1 Blockade
PACAP has neuroprotective roles in preclinical models (stroke, TBI, neurodegeneration). Chronic PAC1 blockade could theoretically reduce neuroprotective reserve. PACAP modulates circadian function—PAC1 blockade could affect light-mediated circadian entrainment. PACAP has immune-modulatory functions—long-term effects on immune function are unknown. These concerns are theoretical and have not been observed in the relatively short exposure windows of Phase 2 data.
PLAIN ENGLISH
Giving PACAP to people causes migraines, flushing, and blood vessel dilation—which is actually useful for research but means no one would take it as a supplement. The antibody that blocks PACAP's receptor is well-tolerated in trials so far—similar to the CGRP antibodies millions of people already take for migraine. The open question is whether blocking PACAP long-term could affect its protective roles in the brain, immune system, or body clock. Those answers will come from larger, longer trials.
Legal and Regulatory Status
No PACAP-based therapeutic is FDA-approved. Lu AG09222 (anti-PAC1 antibody) is in Phase 2b clinical trials for episodic migraine prevention. If Phase 3 is successful, FDA submission could occur in 2027–2028.
PACAP-38 and PACAP-27 are available as research-grade peptides from laboratory suppliers. They are not sold by consumer peptide vendors and are not marketed as supplements. Administering PACAP would trigger migraine and stress responses—there is no consumer use case.
WADA does not list PACAP on its Prohibited List.
Research Protocols and Formulation Considerations
PACAP Migraine Provocation Protocol (Research)
| Parameter | Detail |
|---|---|
| Compound | PACAP-38 (synthetic) |
| Route | IV infusion over 20 minutes |
| Dose | 10 pmol/kg/min |
| Subjects | Migraine patients and healthy controls |
| Measurement | Headache diary, MRA (middle meningeal artery diameter), migraine attack criteria |
| Key timing | Delayed migraine onset 5–6 hours post-infusion |
Anti-PAC1 Antibody Clinical Protocol
| Parameter | Detail |
|---|---|
| Compound | Lu AG09222 (anti-PAC1 monoclonal antibody) |
| Route | Subcutaneous injection |
| Frequency | Monthly |
| Indication | Episodic migraine prevention (≥4 migraine days/month) |
| Phase | 2b (PROCEED trial ongoing) |
Dosing in Published Research
The following table summarizes dosing protocols for PACAP as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.
Published Research Dosing
| Parameter | Detail |
|---|---|
| PACAP provocation | 10 pmol/kg/min IV over 20 minutes |
| Animal ICV | 0.1–1.0 nmol PACAP-38 |
| Anti-PAC1 antibody | SC monthly (dose undisclosed; typical monoclonal antibody range 100–300 mg) |
| Therapeutic PACAP dose | Does not exist — the therapeutic approach is antagonism, not agonism |
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
PACAP has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
Why This Section Is Nearly Empty
PACAP is the opposite of a self-experimentation peptide. Administering exogenous PACAP would trigger migraines in migraine-susceptible individuals and amplify the stress response in everyone. No peptide vendor sells PACAP for consumer use. No biohacking community has a PACAP protocol. The entire clinical interest is in blocking PACAP signaling, not supplementing it. This is a peptide you want less of, not more of, if you are seeking stress reduction or migraine prevention.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into PACAP combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining PACAP with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Related Compounds: How PACAP Compares
PACAP belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Sleep, Stress & Recovery cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Primary Mechanism | Primary Application | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Neuropeptide Y | Neuropeptide (36 aa) | Tier 2 — Clinical Trials | Eyes Open | Y1 receptor anxiolysis, CRH antagonism, HPA axis modulation | Stress resilience, PTSD, anxiety | Phase Ib RCT (intranasal, PTSD) + RCT (MDD) — ~54 patients total | Not approved | Not prohibited | Small early-phase trials; intranasal BBB penetration uncertain |
| Desmopressin | Synthetic vasopressin analog (9 aa, cyclic) | Tier 1 — Approved Drug | Strong Foundation | V2 receptor agonism → antidiuresis → reduced nocturnal urine volume | Nocturnal enuresis, nocturia, central DI | Cochrane review (47 RCTs, N=3,448) + Phase III nocturia (N=757) | Approved (multiple formulations, 1978+) | Not prohibited | Hyponatremia risk; nasal spray withdrawn for enuresis (2007) |
| Corticotropin-Releasing Hormone | Neuropeptide (41 aa) | Tier 4 — Preclinical (therapeutic) | Eyes Open | HPA axis master switch — CRH-R1 activation → ACTH → cortisol | Understanding stress biology; CRH-R1 antagonists for depression (failed) | Biomarker studies (elevated CSF CRH in depression); CRH-R1 antagonist trials failed | Diagnostic only (Acthrel for Cushing's differentiation) | Not prohibited | CRH-R1 antagonists failed in depression trials despite strong mechanistic rationale |
| Orexin | Neuropeptide pair (OxA 33 aa + OxB 28 aa) | Tier 1 — Approved Drug | Strong Foundation | OX1R/OX2R wake promotion; loss → narcolepsy | Insomnia (via DORAs); narcolepsy diagnosis/treatment | 3 Phase III DORA trials (N=4,945 total); CSF orexin diagnostic for narcolepsy | 3 DORAs approved (suvorexant 2014, lemborexant 2019, daridorexant 2022) | Not prohibited (DORAs may be relevant) | DORAs are small molecules not peptides; orexin agonists for narcolepsy still in development |
| Cortistatin | Neuropeptide (14–17 aa, somatostatin-related) | Tier 4 — Preclinical Only | Eyes Open | Cortical activity depression → slow-wave sleep induction; ACh antagonism | Deep sleep promotion (theoretical) | None | Not approved | Not prohibited | No human data; single research group; somatostatin receptor cross-reactivity |
| Galanin | Neuropeptide (29 aa) | Tier 3 — Limited Human Data | Eyes Open | VLPO sleep-switch activation; LC noradrenergic inhibition | Sleep initiation; potential antidepressant | 1 IV study in healthy men: increased REM, preliminary antidepressant signal | Not approved | Not prohibited | Single small human study; 3 receptor subtypes with opposing effects complicate targeting |
| PACAP | Neuropeptide (27–38 aa, VIP family) | Tier 2 — Clinical Trials | Eyes Open | PAC1/VPAC receptor activation → stress amplification + migraine | Migraine prevention (via anti-PAC1 antibody); PTSD genetics | Phase 2 anti-PAC1 antibody (migraine, positive); PTSD genetic association | Not approved (anti-PAC1 Lu AG09222 Phase 2b ongoing) | Not prohibited | Therapeutic = blocking PACAP not administering it; stress/sleep applications undeveloped |
| Melanin-Concentrating Hormone | Neuropeptide (19 aa) | Tier 4 — Preclinical Only | Eyes Open | MCH neuron activation → selective REM sleep promotion | REM sleep regulation; narcolepsy (MCHR1 antagonism) | None clinical | Not approved; HBS-102 IND stage (narcolepsy) | Not prohibited | No human clinical data; obesity MCHR1 programs failed; narcolepsy IND not advanced |
| Cosyntropin | Synthetic ACTH fragment (24 aa) | Tier 1 — Approved Drug | Strong Foundation | MC2R activation → adrenal cortisol production | Adrenal insufficiency diagnosis (ACTH stimulation test) | Millions of diagnostic tests performed worldwide since 1970 | Approved diagnostic (Cortrosyn, 1970). Synacthen Depot therapeutic (EU/UK). | Prohibited (S2 — ACTH analogs) | US diagnostic only; therapeutic use primarily outside US |
Frequently Asked Questions
What is PACAP?
PACAP (pituitary adenylate cyclase-activating polypeptide) is a 38-amino-acid neuropeptide involved in stress signaling, migraine, and circadian rhythm regulation. It was discovered in 1989 and is related to VIP (vasoactive intestinal peptide), sharing 68% of its amino acid sequence.
How does PACAP cause migraines?
PACAP is released from trigeminal sensory nerve terminals around the blood vessels of the meninges. It activates PAC1 receptors, causing sustained vasodilation and sensitization of pain pathways. When PACAP is infused intravenously into migraine patients, 58% develop a full migraine attack with a delayed onset of 5–6 hours.
What is the anti-PAC1 antibody for migraine?
Lu AG09222 (Lundbeck) is a monoclonal antibody that blocks the PAC1 receptor—preventing PACAP from activating migraine pathways. It showed positive Phase 2 results for reducing monthly migraine days and is now in Phase 2b trials. If successful, it would be the first migraine drug targeting the PACAP system.
How does PACAP relate to CGRP?
Both PACAP and CGRP are neuropeptides released by trigeminal nerves during migraine. Both trigger migraine attacks when infused IV. Both are targets for therapeutic antibodies. The CGRP antibodies (erenumab, galcanezumab, fremanezumab) are already approved and widely prescribed. The anti-PAC1 antibody follows the same development model and could help the ~30% of migraine patients who do not respond to CGRP-targeted therapies.
Does a PACAP gene variant really cause PTSD only in women?
A polymorphism (rs2267735) in the PAC1 receptor gene is associated with PTSD diagnosis in women but not men. The mechanism involves an estrogen response element in the gene—estrogen increases PAC1 expression in female risk-allele carriers, enhancing PACAP signaling and potentially increasing stress reactivity. This does not \u0022cause\u0022 PTSD—it is a risk factor that partially explains the 2:1 female-to-male PTSD prevalence ratio.
Can I take PACAP for stress or sleep?
No. PACAP amplifies the stress response and triggers migraines. Taking it would worsen stress and potentially induce migraine attacks. The therapeutic interest is in blocking PACAP signaling—the opposite of supplementation.
How does PACAP relate to CRH?
PACAP and CRH work together in the stress response. PACAP enhances CRH release from hypothalamic PVN neurons, amplifying HPA axis activation and cortisol production. Both are stress-activating peptides in Cluster J. NPY opposes both.
Does PACAP affect the body clock?
Yes. PACAP is co-released with glutamate from retinal ganglion cells to the suprachiasmatic nucleus (the master circadian clock). PACAP modulates how strongly light signals shift the clock. PAC1 knockout animals show altered circadian responses to light. This connects PACAP to the circadian regulation of the sleep-wake cycle.
Is PACAP neuroprotective?
In preclinical models, PACAP has shown neuroprotective effects in stroke, traumatic brain injury, and neurodegeneration. These effects are mediated through PAC1 → cAMP → CREB signaling, which promotes neuronal survival. No human study has tested PACAP for neuroprotection.
Why is PACAP-38 the important form and not PACAP-27?
PACAP-38 is the predominant form in the brain (~90% of brain PACAP). It activates PAC1 with higher efficacy and has a slightly longer half-life than PACAP-27. The provocation studies and antibody trials focus on the PACAP-38/PAC1 interaction. PACAP-27 retains activity but is less physiologically abundant.
Could anti-PAC1 antibodies help PTSD?
The genetic association between PAC1 variants and PTSD in women suggests that PAC1 blockade could theoretically reduce PTSD risk or symptoms in genetically susceptible women. However, no clinical trial has tested this. The current development focus is migraine, not PTSD. A PTSD trial would require selecting for women with the rs2267735 risk allele—a precision-psychiatry approach that has not been implemented.
How does PACAP relate to VIP?
PACAP and VIP share 68% amino acid sequence homology and two receptors (VPAC1, VPAC2). But PACAP has its own selective receptor (PAC1) that VIP does not strongly activate. PACAP is primarily associated with stress and migraine; VIP is primarily immunomodulatory. They are cousins with overlapping but distinct clinical relevance.
Summary of Key Findings
PACAP sits at the intersection of three major clinical stories: migraine pathophysiology, sex-specific PTSD genetics, and circadian regulation. It is a versatile stress-responsive neuropeptide that amplifies the HPA axis alongside CRH, triggers migraine attacks through the trigeminal system, and modulates how light adjusts your body clock.
The clinical pipeline is migraine-focused. The provocation finding—58% migraine attack rate with IV PACAP—established it as a validated human migraine mediator. The anti-PAC1 antibody Lu AG09222 showed positive Phase 2 results and is in Phase 2b, with Phase 3 planned. If approved, it would be the first non-CGRP neuropeptide-targeted migraine therapy and could serve the substantial patient population that does not respond to CGRP antibodies.
The PTSD genetics story is scientifically elegant—a single PAC1 receptor variant that increases PTSD risk in women through an estrogen-dependent mechanism—but has not yielded therapeutics. The circadian role is established in animal models but clinically unexploited. PACAP's therapeutic future, for now, is about blocking it for migraine—not supplementing it for stress or sleep.
Verdict Recapitulation
Evidence Tier 2 — Clinical Trials. Phase 2 positive for anti-PAC1 migraine antibody. Phase 2b ongoing. Validated human migraine provocation. Sex-specific PTSD genetic association.
Verdict: Eyes Open. The migraine pathway is following the CGRP antibody blueprint with real clinical data. The PTSD connection is fascinating but undeveloped. The stress and sleep biology is important but does not yet have a therapeutic outlet. PACAP is a peptide whose clinical story is being written in migraine clinics, not sleep labs.
For readers considering PACAP, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source PACAP
Further Reading and Resources
If you want to go deeper on PACAP, the evidence landscape for sleep, stress & recovery peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Sleep, Stress & Recovery Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: PACAP — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Miyata A, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun. 1989;164(1):567–574 PubMed
- Schytz HW, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009;132(Pt 1):16–25 PubMed
- Ressler KJ, et al. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature. 2011;470(7335):492–497 PubMed
- Lundbeck Press Release. Lu AG09222 Phase 2 results for episodic migraine. New England Journal of Medicine. 2024
- Vaudry D, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009;61(3):283–357 PubMed
- Hannibal J. Pituitary adenylate cyclase-activating peptide in the rat central nervous system: an immunohistochemical and in situ hybridization study. J Comp Neurol. 2002;453(4):389–417 PubMed
- Hammack SE, et al. Roles for pituitary adenylate cyclase-activating peptide (PACAP) expression and signaling in the bed nucleus of the stria terminalis (BNST) in mediating the behavioral consequences of chronic stress. J Mol Neurosci. 2010;42(3):327–340 PubMed
DISCLAIMER
PACAP is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 09, 2026. Next scheduled review: October 06, 2026.